What if a gene-editing cure upends pharma economics?
A gene-editing cure is, like longevity, a thematic repricing the tape barely registers day-one (faint risk-on). The actionable chain is within healthcare: the curative-therapy economics destroy recurring-revenue chronic-treatment franchises (the manufacturer of the displaced standard-of-care) while the platform owner (CRISPR/base-editing) re-rates. Rhymes with the 2017-2019 gene-therapy approvals (Luxturna/Zolgensma) that pressured competing chronic-care names. Skeptic: pricing/reimbursement and durability questions cap the disruption, so size it as a pharma long-short, not a sector bet.
Every number ships with its receipt — the odds, the range, the precedents, and a public grade at Reality Check. The statistical machinery that produces it is proprietary.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (electric blue) over time vs the market's (Polymarket, amber), from the past toward the 3–10 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. Loading the probability audit trail…
What it would mean
If this plays out, it is a mixed shock. A gene-editing cure for a major disease disrupts pharma economics. The trigger decomposes into signed root‑shocks — Risk appetite ▲ — which propagate through our causal graph to the markets below.